Evidence map›Paper›PMID 42505235›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

An Equity-Embedded, Protocol-Agnostic Pre-Trial Navigation Model for Canadian Blood Cancer Trials: Findings from the Myeloma Canada Phase 0 Workshop.

Gabriele Colasurdo, Alvina Nadeem, Nina Mason, Juliette Royer, Stephanie Soltys, Henry Chan, Richard K Plante, Julie Stakiw, Joseph R Mikhael, Michelle Oana

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gabriele ColasurdoMyeloma Canada, Dorval, QC H9P 2V4, Canada.
Alvina NadeemAlvina N. Consulting, Montreal, QC J5Y 0J4, Canada.ORCID 0009-0009-8512-1437
Nina MasonArthur JE Child Comprehensive Cancer Centre, Cancer Care Alberta, Calgary, AB T2N 5G2, Canada.
Juliette RoyerHalton-Peel Myeloma Support Group, Guelph, ON N1H 5V3, Canada.
Stephanie SoltysJohnson & Johnson, Toronto, ON M3C 1L9, Canada.
Henry ChanIndependent Researcher, Toronto, ON M3B 3B4, Canada.ORCID 0000-0002-0156-4655
Richard K PlanteRKP NEXUS Consulting, Toronto, ON M4G 2N5, Canada.ORCID 0009-0003-4584-2252
Julie StakiwSaskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada.
Joseph R MikhaelTranslational Genomics Research Institute (TGen), City of Hope Comprehensive Cancer Center, Phoenix, AZ 85004, USA.ORCID 0000-0001-9670-2864
Michelle OanaMyeloma Canada, Dorval, QC H9P 2V4, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Clinical Trials as TopicMultiple MyelomaCanadaDiversity, Equity, InclusionHumansand inclusionclinical trial navigationclinical trial readinessdiversityequityhealth equityhuman-centred designpatient navigation

Identifiers

PMID42505235
PMCPMC13408120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.